AdAlta Ltd (ASX:1AD)'s Tim Oldham provides an overview of the company's December quarter performance — one he believes sets up the biotech for a strong 2022. Over the period, AdAlta strengthened its cash balance to $9.08 million, providing a funding runway as it develops its lead product, AD-214, as a first in class, next-generation antibody therapy to treat idiopathic pulmonary fibrosis and interstitial lung disease.
AdAlta launches into 2022 with $9.08 million for treatment candidate development
